iX Biopharma Receives $41 Million U.S. Contract for Wafermine Pain Therapy Development
iX Biopharma Ltd has secured approximately $41 million from the U.S. government to develop its Wafermine therapy for pain management. The funding, awarded by the Defense Health Agency, aims to enhance the therapy's commercial viability and prepare it for potential battlefield use. The three-year program seeks Emergency Use Authorization from the FDA and supports Phase 3 development for a New Drug Application.
Theia Market Signal Identification - AI Assisted
iX Biopharma Ltd has obtained about $41 million from the U.S. government to advance its Wafermine therapy for acute moderate to severe pain. The funding, awarded by the Defense Health Agency under an Other Transaction Agreement, will support both commercial use and potential deployment by the Department of Defense.
Over 36 months, the program will work towards securing Emergency Use Authorization from the FDA and facilitate Phase 3 development for a New Drug Application. The contract reflects the government's belief in iX Biopharma's unique position to deliver the therapy via its proprietary WaferiX sublingual delivery technology.
Comments